Amarin seeks to raise $87M to fund omega-3 fatty acid drug
This article was originally published in Scrip
Executive Summary
Irish biotech Amarin 6 January priced a public offering of 12 million American depositary shares (ADS) at $7.60 per share, with expectations of raising $87.1 million.